Search 

LinkedUp Bio, pioneered a novel antibody drug discovery engine that is dedicated to developing novel biological therapeutics for diseases that have limited or no successful treatment.
The gamechanger element is that we can scree the entire natural immune repertoire with unprecedented speed and scales and identified hits rapidly and efficiently, thereby greatly increasing the success rate of potential therapeutics for targets that are hard to drug.

AbLink Platform: Screening the entire immune repertoire for more efficient antibody discovery
LInkedUp Bio is using microfluidic device to enable single B cell encapsulation, and subsequently, extract the information of heavy chain and light chain of antibody from tens of millions of B cells and then transferred them into our in-house engineered yeast system. These antibody copies in the yeast cells maintained their natural heavy chaiin and light chain pair, and good biophysical stabilities of the original B cells. Our yeast strain has both display and secretion mode which enables quick chacterization of the potential hits, eliminating the step for mamamlian expression for further hits validation, a typical bottleneck for many single B cell platfrom.

The AbLink Platform is the only platform allowing comprehensive screening of the natural antibody repertoire. This results in at least 100 times more hits than hybridoma and other single B cell platforms. Other benefits include more extensive epitope coverage, more unique and rare sequences & diversity, higher affinity, and functionality. Currently the platform gathered a great deal of interest in industry as we already collaborated with two biopharmas and several others are in the middle of conversation.

LUB-001 : Tackling malignant melanoma and solid tumors
LinkedUp Bio’s first target indication is malignant melanoma, one of the deadliest forms of human cancer, due to the high incidence of metastases and drug resistance. Extensive research supports the role of a new target X for malignant melanoma, potentially affecting tumor growth, survival and metastasis. However, due to the limitations of traditional antibody discovery technologies and the complex structure of the target, there have been numerous antibody candidates that showed limited efficacy in inhibition of tumor growth, never matched the high expectation and promise of a breakthrough treatment.
LinkedUp developed a novel antibody clone for this target X and in vitro data demonstrated drastically improvement of the ability of the immune system to attack the tumor cells. LinkedUp Bio’s approach can provide a novel promising treatment for many different types of cancer, such as triple negative breast cancer, glioblastoma, hepatocellular carcinoma, and more.
LUB-002: Tackling congenital muscular dystrophy
Alpha Dystrolycanopathy is a clinically and genetically heterogeneous group of muscular dystrophies with the defective matriglycan which links the muscle cells with extracellular matrix . The cause of the defection involved more than 18 genes, and manifested various degree of severity in clinical symptoms. Currently there no effective therapy for this group of diseases. Novel strategies like antisense, AAV gene therapy, enzyme replace can only address one kind gene a time, making a significant commercial challenge. We propose a novel bispecific antibody approach that functions as a surrogate molecular linker to reconnect extracelluar matrix and the muscle cells to ameliorate sarcolemmal fragility, a primary pathology in patients with alpha-dystroglycan- related muscular dystrophies.

We are currently seeking fund to move our program forward and expand our team.

Team:
Greg Li, Co-founder, President
Stephen Gillies, Co-founder, CSO
Tao Wang, Co-founder, Vice President of Antibody Discovery

Jason Lavinder, Cofounder, Advisory Board

Links global business. One hub for the Middle East

Lysoway Therapeutics is an emerging biopharmaceutical company focusing on restoring or enhancing autophagy and lysosomal functions to treat a broad class of diseases.

Company:
Maculus Therapeutix is a preclinical-stage biopharmaceutical company focused on finding practical solutions to treat chronic diseases of the retina and optic nerve such as wetAMD (Age related Macular Degeneration) in the Ophthalmology space with a novel tunable biodegradable proprietary product – MacuBloc™ capable of delivering any FDA approved drugs for Wet AMD to the site of the disease. With its unique suitability for targeted and extended delivery of drugs to back of the human eyes, MacuBloc™ offers significant benefits to Wet AMD patients over existing products: a single intravitreal injection that lasts an year instead of the current 10-12 monthly injections plus significant potential reduction in inflammation, infection, doctor visits and total cost of care compared to current practice.

Market:
The global market size of Age-Related Macular Degeneration (AMD) is currently $7.7B, growing at 7.6% CAGR and is expected to reach a value of $11B by 2025. Current standard of care involves 10-12 monthly injections with a 30 gauge syringe needle going through the eye sclera, often resulting post-injection pain and possible infection due to repeated injections in a small area as well as ruptured blood vessels in the sclera. By reducing the number of injections from 10+ to just ONE, MacuBloc™ formulation is likely to be a treatment of choice.

Our team at the Maryland Department of Commerce assists companies to establish operations and partnerships in one of the leading ecosystems for the life science industry in the United States.
- As one of the nation’s largest and fastest growing biotechnology clusters, Maryland is #1 in Ph.D. concentration in biological fields, employed doctoral scientists, and was recognized last year at the 4th best biotechnology cluster in the nation by Genetic Engineering and Biotechnology News.
- We have facilitated access to 74 Federal laboratories, including the National Institutes of Health, the National Institute for Standards and Technology, the Food and Drug Administration, and the Walter Reed Army Institute of Research.
- We can reach 80% of the U.S. pharmaceutical industry and four nearby international airports to enable efficient travel.
- Maryland’s Cost of Doing Business Index is 16%, 12%, and 10% lower than in Boston, New Jersey, and California, respectively, according to Moody’s Analytics Regional Financial Review. In our industry, that translates to a lower cost of operations and wet lab space.
- The cost of living in Maryland can be up to one-and-a-half times lower than in the metropolitan areas of New York, Boston, and San Francisco, according to the Council for Community and Economic Research.

MaveriX Oncology is exploiting cancer and immune cell metabolism to discover and develop new targeted therapeutics that challenge the limitations of current chemotherapy and immunotherapy. The MaveriX technology approach is a multi-target, multi-asset small-molecule platform with potential first and best-in-class therapeutics designed for monotherapy and combination chemotherapy and immunotherapy. Our experienced team of pharma executives is developing a proprietary pipeline of drug candidates with the goal of bring new and improved treatments to patients that suffer from cancer. Our lead program MVX5005 (E037) is well tolerated and exhibits broad, single- agent anti-tumor activity in preclinical mouse models of cancer. The unique mechanism-of-action targets cancer cells directly, induces immunogenic cell death while eradicating immune suppressive cells within the tumor microenvironment. E037 is currently completing IND-enabling studies targeting clinical entry Q3 2021. The company is currently raising capital and seeking strategic partnership opportunities to support clinical development to POC with differentiated platform expansion.

MaveriX Oncology, Inc., is a globally-orientated biotechnology company focused on the discovery and development of novel targeted small-molecule chemo-immunotherapies. The MaveriX technology approach exploits oncogenic and immunogenic targets that are over-expressed to a high frequency in the majority of solid tumors and hematological malignancies. This is a multi-target, multi-asset small-molecule platform technology with potential first and best-in-class therapeutics designed primarily for monotherapy activity in the clinic but with a robust mechanistic rational for combination chemotherapy and immunotherapy. Our experienced team of pharma executives is developing a proprietary pipeline of drug candidates with the goal of bringing new and improved treatments to patients suffering from cancer. Our lead program MVX5005 (E037) is well tolerated with broad single agent anti-tumor activity, can overcome key resistance mechanisms in cancer, and challenge the limitations of current chemotherapy and immunotherapy approaches. MVX5005 is currently completing formal IND-enabling studies, targeting clinical entry beginning Q3 2021 (phase 1a dose escalation with disease-specific expansion cohorts for monotherapy plus phase 1b combination chemotherapy and immunotherapy).

MedSci Healthcare was established in 2002 with the creation of Bioon.com, with headquarters in Shanghai and internationally in the U.S. We are committed to be the bridge between China and the U.S. healthcare. This is done by connecting Chinese healthcare professionals (HCPs) with U.S. resources and vice versa.
The company has done projects with major companies such as: Pfizer, Harvard Medical School, AstraZeneca, GSK, Abbott, Johnson & Johnson, Takeda, Novartis, Medtronic and many more. We have also worked with organizations such as the China Cardiovascular Association (CCA), Chinese Medical Doctor Association (CMDA) and more.
MedSci is a digital academic platform, scientific publishing support and multichannel marketing (MCM) organization. We use the term Academic Promotion Organization (APO). We use scientific writers, doctors & researcher scientists and commercialization experts to develop customized strategy & implementation to reach each organization’s goals.

Life Sciences venture capital fund with three funds under management.